ruzinurad   Click here for help

GtoPdb Ligand ID: 14659

Synonyms: compound 41 [PMID: 26704267] | Ruiming® (China) | SHR-4640 | SHR4640
Approved drug
ruzinurad is an approved drug
Compound class: Synthetic organic
Comment: Ruzinurad (SHR-4640) is a selective, orally bioavailable urate anion exchanger 1 (URAT1; SLC22A12) inhibitor [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 74.96
Molecular weight 338.22
XLogP 1.34
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CC(C1)(C(=O)O)SC2=CC=NC3=CC=C(C=C32)Br
Isomeric SMILES C1CC(C1)(C(=O)O)SC2=C3C=C(C=CC3=NC=C2)Br
InChI InChI=1S/C14H12BrNO2S/c15-9-2-3-11-10(8-9)12(4-7-16-11)19-14(13(17)18)5-1-6-14/h2-4,7-8H,1,5-6H2,(H,17,18)
InChI Key QGBWIYLNOBYNDL-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Ruzinurad (SHR-4640) was progressed as a clinical candidate for the treatment of hyperuricemia. First approval for this indication was granted by China's NMPA in May 2026 [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04052932 A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT04956432 A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout Phase 3 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT07362355 The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia Phase 2 Interventional Jiangsu HengRui Medicine Co., Ltd.
NCT03185793 Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia Phase 2 Interventional Jiangsu HengRui Medicine Co., Ltd. 1